Effects of Human Immunodeficiency Virus Infection on Recurrence of Tuberculosis after Rifampin-Based Treatment: An Analytical Review

Korenromp, Eline L.; Scano, Fabio; Williams, Brian G.; Dye, Christopher; Nunn, Paul
July 2003
Clinical Infectious Diseases;7/1/2003, Vol. 37 Issue 1, p101
Academic Journal
We reviewed 47 prospective studies of recurrence of pulmonary tuberculosis (TB) after cure to assess the influence of human immunodeficiency virus (HIV) infection and rifampin treatment. Multivariate regression revealed that the recurrence rate for HIV-uninfected persons increased with decreasing duration of therapy: it was 1.4 cases per 100 person-years for recipients of ⩾ 7 months of rifampin therapy and 2.0 and 4.0 cases per 100 person-years for recipients of 5-6 and 2-3 months of rifampin therapy, respectively (trend P = .00014), over a mean follow-up duration of 34 months, at a TB incidence of 250 cases per 100,000 person-years. Relative risks of recurrence associated with HIV infection at these 3 treatment durations were 2.2, 2.1, and 3.4, respectively, with a significant interaction between HIV infection status and treatment duration (P = .025). The recurrence rate increased with the background TB incidence (P = .048), and it decreased over time since completion of treatment in HIV-uninfected but not in HIV-infected patients (overall trend, P = .00008; difference by HIV infection status, P = .025). In countries where HIV infection is endemic, TB recurrence may be reduced by administration of rifampin-based treatment for at least 6 months, in accordance with World Health Organization recommendations.


Related Articles

  • Ritonavir Enables Combined Therapy with Rifampin and Saquinavir. Veldkamp, A .I.; Hoetelmans, R. M. W.; Beijnen, J. H.; Mulder, J. W.; Meenhorst, P. L. // Clinical Infectious Diseases;12/1/1999, Vol. 29 Issue 6, p1586 

    Examines whether ritonavir enables the treatment of coinfection by HIV-1 and Mycobacterium tuberculosis with saquinavir and rifampin. Standard of care for the treatment of HIV-1 infection; Pharmacokinetic profiles of saquinavir in patients treated with combinations of ritonavir, saquinavir and...

  • Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis.  // MMWR: Morbidity & Mortality Weekly Report;3/28/2014, Vol. 63 Issue 12, p272 

    The article reports on updated guidelines for managing possible pharmacologic interactions in treating human immunodeficiency virus (HIV) infection and tuberculosis (TB) as of March 2014. It notes that these include recommendations for use of newer antiretroviral drugs, and rifampin with...

  • The incidence of recurrence of tuberculosis and its related factors in smear-positive pulmonary tuberculosis patients in Iran: A retrospective cohort study. Moosazadeh, Mahmood; Bahrampour, Abbas; Nasehi, Mahshid; Khanjani, Narges // Lung India;Nov/Dec2015, Vol. 32 Issue 6, p557 

    Background and Aim: Studying the recurrence of smear-positive pulmonary tuberculosis (TB) is a convenient way to evaluate the effectiveness of TB control programs and identify vulnerable patients. In the present study, the rate of recurrence of TB and its predictors were determined in Iran....

  • Efavirenz/rifampicin interaction.  // Reactions Weekly;5/30/2009, Issue 1254, p21 

    The article describes the case of a 46-year-old man who became agitated and experienced high efavirenz plasma concentrations during efavirenz treatment for HIV infection and rifampicin for tuberculosis. With a history of Takayasu arteritis and hepatitis C and HIV infections, he started taking...

  • Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients. Ramachandran, Geetha; Kumar, A. K. Hemanth; Ponnuraja, C.; Ramesh, K.; Rajesh, Lakshmi; Chandrasekharan, C.; Swaminathan, Soumya // Indian Journal of Medical Research;Dec2013, Vol. 138 Issue 6, p955 

    Background & objectives: Among patients with HIV-associated tuberculosis (TB), reduced plasma non-nucleoside reverse transcriptase inhibitors (NNRTI) concentrations during rifampicin (RMP) co-administration could lead to HIV treatment failure. This study was undertaken to examine the association...

  • Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa. Cox, Helen S.; McDermid, Cheryl; Azevedo, Virginia; Muller, Odelia; Coetzee, David; Simpson, John; Barnard, Marinus; Coetzee, Gerrit; van Cutsem, Gilles; Goemaere, Eric // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: Although multidrug-resistant tuberculosis (MDR-TB) is emerging as a significant threat to tuberculosis control in high HIV prevalence countries such as South Africa, limited data is available on the burden of drug resistant tuberculosis and any association with HIV in such settings....

  • African health ministers commit to ramped up TB/HIV treatment.  // Africa Health;May2013, Vol. 35 Issue 4, p15 

    The article reports that health ministers from South Africa and Swaziland have committed to change the diagnosis and treatment of tuberculosis and human immune virus (HIV).

  • Researchers Claim New Compound Treats HIV, TB.  // India -- West;6/24/2011, Vol. 36 Issue 31, pA40 

    The article reports that the Tuberculosis Research Centre researchers in Tamil Nadu, India have claimed to have invented a compound, called "Transitmycin," which treats tuberculosis (TB) and HIV viruses.

  • Fighting the monster. Maxmen, Amy // Nature;7/15/2010 Supplement, Vol. 466 Issue 7304, pS18 

    The article focuses on the health impact and treatment of HIV and tuberculosis (TB) co-infection among the people in Africa. It states that HIV and TB co-infection can be destructive, can cause weight loss, pneumonia and pneumonia, and death. It stresses that simultaneous treatment of both HIV...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics